ATE435031T1 - Methode und zusammensetzung zur angiogenese- inhibierung mit antagonisten gegen mmp-9 und beta1-integrine - Google Patents

Methode und zusammensetzung zur angiogenese- inhibierung mit antagonisten gegen mmp-9 und beta1-integrine

Info

Publication number
ATE435031T1
ATE435031T1 AT00950330T AT00950330T ATE435031T1 AT E435031 T1 ATE435031 T1 AT E435031T1 AT 00950330 T AT00950330 T AT 00950330T AT 00950330 T AT00950330 T AT 00950330T AT E435031 T1 ATE435031 T1 AT E435031T1
Authority
AT
Austria
Prior art keywords
antagonists
composition
mmp
beta1 integrins
protein
Prior art date
Application number
AT00950330T
Other languages
English (en)
Inventor
Peter Brooks
Loubna Hassanieh
Dorothy Rodriguez
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Application granted granted Critical
Publication of ATE435031T1 publication Critical patent/ATE435031T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00950330T 1999-07-13 2000-07-13 Methode und zusammensetzung zur angiogenese- inhibierung mit antagonisten gegen mmp-9 und beta1-integrine ATE435031T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14358199P 1999-07-13 1999-07-13
US15249599P 1999-09-02 1999-09-02
PCT/US2000/019095 WO2001004157A2 (en) 1999-07-13 2000-07-13 NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND β1 INTEGRINS

Publications (1)

Publication Number Publication Date
ATE435031T1 true ATE435031T1 (de) 2009-07-15

Family

ID=26841194

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00950330T ATE435031T1 (de) 1999-07-13 2000-07-13 Methode und zusammensetzung zur angiogenese- inhibierung mit antagonisten gegen mmp-9 und beta1-integrine

Country Status (10)

Country Link
US (1) US7566449B2 (de)
EP (1) EP1203025B1 (de)
JP (1) JP2003508352A (de)
CN (1) CN1379685A (de)
AT (1) ATE435031T1 (de)
AU (1) AU783019B2 (de)
CA (1) CA2379373A1 (de)
DE (1) DE60042487D1 (de)
ES (1) ES2327812T3 (de)
WO (1) WO2001004157A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041787B2 (en) 2000-12-29 2006-05-09 Kimberly-Clark Worldwide, Inc. Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases
WO2004110478A1 (en) * 2003-06-19 2004-12-23 Ctt Cancer Targeting Technologies Oy Inhibitors of cell migration
US7390885B2 (en) 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US20090131303A1 (en) * 2007-11-16 2009-05-21 Bor-Shyue Hong Methods and compositions for treating dry eye
AU2008338421A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins
NZ587440A (en) 2008-02-05 2013-01-25 Pfizer Antibodies specific for human integrin alpha 5 - beta 1 and their uses for treating tumours
WO2009111450A2 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 binding proteins
AU2009221916A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
WO2011028883A2 (en) * 2009-09-03 2011-03-10 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
KR101930179B1 (ko) 2010-08-27 2018-12-17 길리아드 바이오로직스, 인크. 매트릭스 메탈로프로테이나제 ９에 대한 항체
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
NZ629178A (en) 2012-02-29 2016-09-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
AU2012318302C1 (en) 2012-02-29 2017-06-15 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5320970A (en) * 1987-11-06 1994-06-14 Washington Research Foundation Detection of collagen degradation in vivo
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3105629B2 (ja) 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
US6132976A (en) * 1992-12-04 2000-10-17 Shriners Hospitals For Children Immunoassays for the measurement of collagen denaturation and cleavage in cartilage
CA2148132A1 (en) 1992-12-04 1994-06-23 Anthony Robin Poole Immunoassay for the measurement of collagen cleavage in cartilage
US5541295A (en) * 1993-02-12 1996-07-30 The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations Detection of type II collagen and its peptides
JP2703116B2 (ja) 1993-07-28 1998-01-26 ベーリンガー マンハイム ゲーエムベーハー コラーゲンまたはコラーゲン断片を検出するためのイムノアッセイ
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5763272A (en) * 1994-12-23 1998-06-09 Boehringer Mannheim Gmbh Hybridoma for producing antibody for collagen I
WO1997044059A2 (en) 1996-05-23 1997-11-27 Shriner's Hospitals For Children Cartilage type ii collagen as an angiogenic factor
US6492508B1 (en) 1996-06-03 2002-12-10 United States Surgical Corp. A Division Of Tyco Healthcare Group Nucleic acids encoding extracellular matrix proteins
GB9702252D0 (en) 1997-02-06 1997-03-26 Univ Sheffield Medical The Sch Collagen assay
US5972623A (en) * 1997-07-31 1999-10-26 Metra Biosystems, Inc. Collagen-peptide assay method
US6030792A (en) 1997-11-13 2000-02-29 Pfizer Inc Assays for measurement of protein fragments in biological media
CA2328414C (en) * 1998-05-08 2014-04-15 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US7101975B1 (en) * 1999-07-13 2006-09-05 University Of Southern California Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins

Also Published As

Publication number Publication date
ES2327812T3 (es) 2009-11-04
EP1203025A2 (de) 2002-05-08
CA2379373A1 (en) 2001-01-18
JP2003508352A (ja) 2003-03-04
US20060062777A1 (en) 2006-03-23
AU783019B2 (en) 2005-09-15
CN1379685A (zh) 2002-11-13
WO2001004157A2 (en) 2001-01-18
AU6344700A (en) 2001-01-30
WO2001004157A9 (en) 2002-07-25
US7566449B2 (en) 2009-07-28
EP1203025B1 (de) 2009-07-01
WO2001004157A3 (en) 2001-05-17
DE60042487D1 (de) 2009-08-13

Similar Documents

Publication Publication Date Title
DE60042487D1 (de) Methode und zusammensetzung zur angiogenese-inhibierung mit antagonisten gegen mmp-9 und beta1-integrine
ATE439369T1 (de) Methode und zubereitung zur hemmung von angiogenese
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
CY1105616T1 (el) ΠΕΠΤΙΔΙΑ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TGFβ1
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
KR960022562A (ko) 항-αV-인터그린 모노크로날 항체
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
ATE333888T1 (de) Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
DK1347730T4 (da) Rekombinante anti-CD30-antistoffer og anvendelser deraf
WO2001007595A3 (en) Novel fibroblast growth factor and nucleic acids encoding same
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
PT1548032E (pt) Péptidos kdr e vacinas que os contêm
ATE514715T1 (de) Monoklonaler anti-met-antikörper, fragmente und vektoren davon zur behandlung von tumoren und entsprechende produkte
WO2006087637A3 (en) Anti her2/neu antibody
WO2006090810A3 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
ATE421531T1 (de) Apoptose-bezogene verbindungen und deren verwendung
DE60143818D1 (de) Alpha-fetoprotein-peptide und ihre verwendung
DE69810513D1 (de) Mimetika von beta-faltblatt und verfahren zur verwendung davon
CY1109946T1 (el) Τροποποιημενα πεπτιδια και η χρηση τους για τη θεραπεια αυτοανοσων νοσων
ATE290881T1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
DE69932834D1 (de) Chi-Conotoxinpeptide als Inhibitoren neuronaler Amintransporter
DK2289533T3 (da) Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties